Al's Comment:

This edition of the Tocagen newsletter shows that the company has a lot of confidence in their brain tumor treatment. They added Dr. Das as vice president of clinical development and medical affairs. She played a huge part in the FDA approval process for Avastin for GBMS.

They also got approval from the FDA to start a newtrial which if successful will allow them to apply for FDA approval. The newsletter also has links to a lot of presentations made about this treatment, and also mentions the Musella Foundation! (We gave a grant to support preclinical testing of Toca 511 with 5-ALA or tumor treating fields!)

 (Disclaimer: Tocagen is a sponsor of our organization)

---

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: https://www.tocagen.com/tocagen-newsletter-june-2015/

---

---

---

(Everything below this line is from virtualtrials.org!)

---

Click HERE to return to brain tumor news headlines.